IDIX Stock News 5.71 05/13/2014 18:37:09 Idenix Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Idenix Pharmaceuticals (IDIX) 5.71 $IDIX

Post Earnings Update: Idenix Pharmaceuticals Has Sunk 7.6% Lower in Past Week (IDIX)
Comtex SmarTrend(R) - Mon May 12, 12:06PM CDT
When Idenix Pharmaceuticals (NASDAQ:IDIX) reported earnings 11 days ago on May 1st, 2014, analysts, on average, expected the company to report a loss of $0.20 on sales of $558.0 thousand. The company actually reported a loss of $0.24 per share on sales of $0.0 thousand, missing EPS estimates by $0.04 and missing revenue estimates by $0.6 million. Shares of Idenix Pharmaceuticals have slipped from $5.54 to $5.12, representing a loss of 7.6%, since the company reported earnings 11 days ago.

Biotech Stocks on our Radar -- Research on ImmunoGen, Idenix Pharma, Repligen, and Vanda Pharma
PR Newswire - Fri May 09, 12:22PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the session at 16,550.97, up 0.20% and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has gained 0.78% in the previous one month. Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Repligen Corp. (NASDAQ: RGEN) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free technical research on IMGN, IDIX, RGEN and VNDA can be downloaded upon signing up at:

Idenix Pharmaceuticals Down 17.0% Since SmarTrend Downtrend Call (IDIX)
Comtex SmarTrend(R) - Thu May 08, 11:06AM CDT
SmarTrend identified a Downtrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on March 26th, 2014 at $6.30. In approximately 1 month, Idenix Pharmaceuticals has returned 16.98% as of today's recent price of $5.23.

Idenix's Q1 Loss Widens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 9:11AM CDT
Idenix's (IDIX) loss widens in the first quarter of 2014.

Idenix Pharmaceuticals Reports First Quarter 2014 Financial Results and HCV Pipeline Review
GlobeNewswire - Thu May 01, 3:11PM CDT
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2014.

Shares of IDIX Down 15.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 01, 9:57AM CDT
SmarTrend identified a Downtrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on March 26th, 2014 at $6.30. In approximately 1 month, Idenix Pharmaceuticals has returned 15.48% as of today's recent price of $5.33.

Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences
GlobeNewswire - Wed Apr 30, 7:14AM CDT
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will host a fireside chat at the Deutsche Bank Securities 39 Annual Health Care Conference on Wednesday, May 7, 2014 at 3:30 p.m. ET at the InterContinental in Boston, MA. Idenix management will also present a corporate overview at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014 at 8:00 a.m. PT at the Encore at the Wynn in Las Vegas, NV, and at the 2014 UBS Global Healthcare Conference on Monday, May 19, 2014 at 8:00 a.m. ET at the Sheraton New York Hotel in New York, NY.

Downtrend Call Working As Idenix Pharmaceuticals Stock Falls 12.5% (IDIX)
Comtex SmarTrend(R) - Thu Apr 24, 9:22AM CDT
SmarTrend identified a Downtrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on March 26th, 2014 at $6.30. In approximately 4 weeks, Idenix Pharmaceuticals has returned 12.54% as of today's recent price of $5.51.

Idenix Pharmaceuticals Has Returned 11.7% Since SmarTrend Recommendation (IDIX)
Comtex SmarTrend(R) - Fri Apr 11, 11:17AM CDT
SmarTrend identified a Downtrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on March 26th, 2014 at $6.30. In approximately 2 weeks, Idenix Pharmaceuticals has returned 11.75% as of today's recent price of $5.56.

Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:55PM CDT
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.

Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
PR Newswire - Tue Apr 08, 12:15PM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative. A number of stocks saw large movements, including Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Free technical research on PPHM, AGIO, IDIX and LXRX can be downloaded upon signing up at:

Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:51AM CDT
Idenix Pharmaceuticals Inc. was a big mover last session, as its shares rose over 12% on the day.

Why Idenix Pharmaceuticals, B&G Foods, and Petrobras Rose Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 07, 7:02PM CDT
Last week's memories of near-record closes for the Dow Jones Industrials faded further into the background Monday, as the Dow posted a decline of more than 1% amid growing concerns about the market's valuation. Even though more volatile sectors of...

MannKind vs. Idenix: Better Biotech Buy
David Williamson, The Motley Fool - Motley Fool - Mon Apr 07, 6:17PM CDT
In this video after a big day in the biotech sector, Motley Fool health-care analyst David Williamson takes investors through today's big winner and loser. Idenix is the winner for the day, up 10% after posting solid results in a...

Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Why Idenix Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 07, 12:12PM CDT
What: Shares of Idenix Pharmaceuticals , a clinical-stage biopharmaceutical company developing therapies to treat human viral diseases, jumped as much as 14% after reporting data and updating the progress of its nucleotide prodrug inhibitor...

Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C
GlobeNewswire - Mon Apr 07, 6:06AM CDT
-- Idenix Reports Positive Proof-of-Concept Data for Lead Nucleotide Prodrug, IDX21437

52.5% Return Seen to Date on SmarTrend Idenix Pharmaceuticals Call (IDIX)
Comtex SmarTrend(R) - Tue Mar 25, 9:14AM CDT
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 5 months, Idenix Pharmaceuticals has returned 52.54% as of today's recent price of $6.75.

Idenix Announces Nucleotide Prodrug (IDX21437) and NS5A Inhibitor (Samatasvir) Poster Presentations at 49th Annual Meeting of the European Association for the Study of the Liver
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced three poster presentations featuring clinical and preclinical data for the Company's nucleotide prodrug, IDX21437, and for samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor, at The International Liver Congress(TM) 2014, the 49th annual meeting of the European Association for the Study of the Liver (EASL), taking place in London, April 9-13, 2014. Full abstracts can now be viewed at the EASL Congress website.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 257

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 15

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 138

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 46

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 297

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 0

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 130

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
Ideas Abu Dhabi Puts Water Innovation on Stage

Updated Category News Views 25

Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 26

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading

Top 5 Most Recently Viewed Articles

Enhanced Insurance Solutions for Virginians Amid Rising Costs

Updated Category News Views 130

Understanding the Rising Costs of Bodily Injury Claims Bodily injury costs in Virginia are on the rise, impacting the financial health of many residents. Unforeseen incidents, from car accidents to dog bites, can swiftly escalate into significant financial burdens. Reports indicate that liability claims have surged, with the average payout increasing significantly since...

Continue Reading
Investors Notify: Class Action Suit Against Lockheed Martin

Updated Category News Views 245

Overview of the Class Action Lawsuit Bragar Eagel & Squire, P.C. has recently announced the initiation of a class action lawsuit against Lockheed Martin Corporation (NASDAQ: LMT). This lawsuit is intended for all individuals and entities that acquired Lockheed Martin securities during the designated class period, which spans from January 23, 2024, to July 21, 2025. The...

Continue Reading
Market Trends Lead MUJ Stock to New Yearly Low of $10.97

Updated Category News Views 186

Understanding the Decline of MUJ Stock In a challenging economic landscape, BlackRock's MuniHoldings New Jersey Quality Fund (MUJ) stock has faced significant declines, recently hitting a 52-week low of $10.97. This shift in value reflects broader market trends affecting municipal bond funds and investor sentiment towards interest rates and credit risk. Key Indicators Of...

Continue Reading
Public Service Company of New Mexico Announces Q1 Dividend

Updated Category News Views 92

Public Service Company of New Mexico Announces Quarterly Dividend The Board of Directors at Public Service Company of New Mexico, part of TXNM Energy (NYSE: TXNM), has officially declared its regular quarterly dividend. This announcement marks a continued commitment to returning value to shareholders. The declared dividend stands at $1.145 per share, attributed to the...

Continue Reading
Nations Photo Lab Earns Recognition for Premium Photo Services

Updated Category News Views 437

Nations Photo Lab Recognized for Outstanding Photo Services In an exciting development within the photo printing sector, Nations Photo Lab has been acknowledged as a leading provider of premium photo printing and framing services. This recognition highlights the increasing demand for unique and high-quality wall art in both residential and commercial spaces. The rise of...

Continue Reading